Cyclacel Reports Third Quarter 2012 Financial Results

[at noodls] – – Enrollment in SEAMLESS Phase 3 study of sapacitabine proceeding as planned; updated survival data from the pilot/lead-in stage of SEAMLESS to be presented at the upcoming annual meeting of the American … more

View todays social media effects on CYCC

View the latest stocks trending across Twitter. Click to view dashboard